Endogenous Bufadienolides, Fibrosis and Preeclampsia

Area of Science:

• Reproductive Medicine
• Cardiovascular Physiology
• Endocrinology

Background:

• Preeclampsia remains a leading cause of maternal mortality and morbidity worldwide, with no decreasing frequency.
• Existing understanding of preeclampsia etiology and pathogenesis requires further elucidation to develop effective treatments.
• The Na/K-ATPase system and its endogenous ligands are implicated in various physiological and pathological processes.

Purpose of the Study:

• To present the novel "fibrotic concept" regarding the etiology and pathogenesis of preeclampsia.
• To highlight the role of the Na/K-ATPase system and its endogenous ligand, marinobufagenin, in preeclampsia.
• To introduce potential new therapeutic strategies for preeclampsia based on modulating this system.

Main Methods:

• Review of existing literature on preeclampsia, Na/K-ATPase, and marinobufagenin.
• Conceptual synthesis to propose the "fibrotic concept" of preeclampsia.
• Discussion of therapeutic approaches including immunoneutralization and mineralocorticoid antagonists.

Main Results:

• The "fibrotic concept" posits that the Na/K-ATPase system, influenced by marinobufagenin, plays a central role in preeclampsia.
• Marinobufagenin, an endogenous ligand, interacts with Na/K-ATPase, contributing to the disease's pathogenesis.
• Therapeutic modulation of the Na/K-ATPase system, specifically targeting marinobufagenin, shows promise.

Conclusions:

• The Na/K-ATPase system and marinobufagenin are critical components in the fibrotic pathway of preeclampsia.
• Targeting marinobufagenin via immunoneutralization or using mineralocorticoid antagonists offers a novel therapeutic avenue.
• This fibrotic concept provides a new framework for understanding and treating preeclampsia.